TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
Treating brain diseases is extraordinarily challenging, because drugs often work poorly and implants require risky surgery that can jeopardize critical brain functions. A group at MIT has sought a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results